Instituto de Salud Carlos III -ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2022

  1. Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?

    Cellular and Molecular Neurobiology, Vol. 42, Núm. 3, pp. 489-500

2021

  1. The coronavirus disease 2019 (Covid-19): Key emphasis on melatonin safety and therapeutic efficacy

    Antioxidants, Vol. 10, Núm. 7

2020

  1. Detection of neurological and ophthalmological pathologies with optical coherence tomography using retinal thickness measurements: A bibliometric study

    Applied Sciences (Switzerland), Vol. 10, Núm. 16

  2. Melatonin reduces NLRP3 inflammasome activation by increasing α7 nAChR-mediated autophagic flux

    Antioxidants, Vol. 9, Núm. 12, pp. 1-18

  3. Melatonin's efficacy in stroke patients; a matter of dose? A systematic review

    Toxicology and Applied Pharmacology, Vol. 392

  4. Scientific production on melatonin from a bibliometric perspective

    Melatonin: Production, Functions and Benefits (Nova Science Publishers, Inc.), pp. 1-17

2019

  1. Potential of melatonin as adjuvant therapy of oral cancer in the era of epigenomics

    Cancers, Vol. 11, Núm. 11

2018

  1. A history of the pharmacological treatment of bipolar disorder

    International Journal of Molecular Sciences, Vol. 19, Núm. 7